As a unique cytosine analog, decitabine was initially recognized as a therapeutic agent for hematologic malignancies, including myelodysplastic syndromes (MDS) and CML, where it reactivates anti-tumor genes like p15INK4b, HIC1, p21CIP1, and p57KIP2 and upregulates CTAs like SPAN-Xb [173–176]. This evidence concerns the gene CDKN2B and myelodysplastic syndrome.